Nippon India PHARMA Fund - G

NAV ₹227.604 ↑ 0.44 (0.19 %) as on 20 Oct 20

Table of Contents

Scheme Objective
NAV Price Chart
Returns
- Historical Returns
- Compounded Returns
Growth Of 10k Over Years
Holdings / Portfolio
All Plan & Options
Fund Manager Information
Custodians
Registrar & Transfer Agent (RTA)
Administrator Companies
Auditors

Scheme Objective

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

Nippon India Pharma Fund is a Equity - Sectoral fund launched on 5 Jun 04. It is a fund with High risk and has given a CAGR return of 21% since its launch. Ranked 35 in Sectoral category. Return for 2019 was 1.7% , 2018 was 3.6% and 2017 was 7.6% .

Below is the key information for Nippon India Pharma Fund

NAV as on 20 Oct 20	₹227.604 ↑ 0.44 (0.19 %)
Net Assets (AUM) as on 30 Sep 2020	₹3,911 Cr.
Launch Date	5 Jun 2004
Category	Equity - Sectoral
Rating	☆☆
Type	Open Ended Fund
Risk	High
AMC	Nippon Life Asset Management Ltd.

Alpha Ratio	4.83
Expense Ratio	2.33 %
Sharpe Ratio	1.672
Information Ratio	1.02
Benchmark	Not Available
Min Investment	₹5,000
Min SIP Investment	₹100
Exit Load	0-1 Years (1%),1 Years and above(NIL)

NAV Price Chart

Returns

Annual Compounded Returns

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 20 Oct 20

Duration	Returns
1 Month	-2.6%
3 Month	15.9%
6 Month	28.7%
1 Year	59.7%
3 Year	19.6%
5 Year	7.8%
10 Year
15 Year
Since launch	21%

Historical Annual Returns

Historical performance (Yearly) on absolute basis

Year	Returns
2019	1.7%
2018	3.6%
2017	7.6%
2016	-10.6%
2015	19.4%
2014	49.5%
2013	20.9%
2012	34.8%
2011	-11%

Growth of 10k Over Years

Date	Value
30 Sep 15	₹10,000
30 Sep 16	₹9,404
30 Sep 17	₹8,381
30 Sep 18	₹10,297
30 Sep 19	₹9,129
30 Sep 20	₹14,672

Nippon India PHARMA Fund Growth 10k Chart

Asset Allocation

Asset Class	Value
Cash	3.25%
Equity	96.75%

Sector Allocation

Sector	Value
Health Care	96.75%

Nippon India PHARMA Fund Equity Allocation

Top Securities Holdings / Portfolio

Holdings/Securities

Name	Global Industry	Holding	Value	Quantity
Lupin Ltd (Healthcare) Equity, Since 31 Aug 08 \| 500257	Drug Manufacturers - Specialty & Generic	10%	₹403 Cr	4,000,025
Aurobindo Pharma Ltd (Healthcare) Equity, Since 31 Dec 15 \| AUROPHARMA	Drug Manufacturers - Specialty & Generic	10%	₹391 Cr	4,910,000 ↑ 610,000
Sun Pharmaceuticals Industries Ltd (Healthcare) Equity, Since 31 Oct 09 \| SUNPHARMA	Drug Manufacturers - Specialty & Generic	10%	₹380 Cr	7,600,976 ↑ 400,000
Dr Reddy's Laboratories Ltd (Healthcare) Equity, Since 30 Jun 11 \| 500124	Drug Manufacturers - Specialty & Generic	10%	₹376 Cr	725,000 ↓ -85,000
Divi's Laboratories Ltd (Healthcare) Equity, Since 31 Mar 12 \| DIVISLAB	Drug Manufacturers - Specialty & Generic	9%	₹366 Cr	1,200,075
Cipla Ltd (Healthcare) Equity, Since 31 May 08 \| 500087	Drug Manufacturers - General	9%	₹364 Cr	4,700,000
Thyrocare Technologies Ltd (Healthcare) Equity, Since 31 May 16 \| THYROCARE	Diagnostics & Research	6%	₹216 Cr	2,854,919 ↑ 25,811
Fortis Healthcare Ltd (Healthcare) Equity, Since 31 Aug 18 \| 532843	Medical Care Facilities	5%	₹195 Cr	14,403,541
Cadila Healthcare Ltd (Healthcare) Equity, Since 31 Jan 18 \| 532321	Drug Manufacturers - Specialty & Generic	4%	₹158 Cr	3,998,982
Sanofi India Ltd (Healthcare) Equity, Since 30 Jun 04 \| 500674	Drug Manufacturers - General	4%	₹151 Cr	175,000

1 - 10 of 27

Ready to Invest?
Talk to our investment specialist

Fund Managers

Name	Since	Tenure
Sailesh Raj Bhan	1 Apr 05	15.51 Yr.
Kinjal Desai	25 May 18	2.35 Yr.

Custodians

Company	Address
Deutsche Bank AG	Deutsche Bank AG,Kodak House, 22, D.N. Road,

Registrar & Transfer Agent

KFin Technologies Private Limited
Address	"KARVY HOUSE",46, Avenue 4, Street No.1,,Banjara Hills,
FAX	91-40-23311968
Email	mailmanager@karvy.com

Administrator Companies

Company	Address
Nippon India Mutual Fund	9th Floor, Crescenzo, C-38 & 39,,G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400051

Auditors

Company	Address
Haribhakti & Co. Chartered Accountants	42, Free Press House,4th Floor,,215, Nariman Point,

All Plan & Options

Fund and Plan	NAV	6 Month	1 Year	3 Year	5 Year
Nippon India Pharma Fund Normal Dividend, Payout	₹71.6063 ↑ 0.14	28.66 %	58.13 %	18.77 %	7.4 %
Nippon India Pharma Fund Normal Dividend, Reinvestment	₹71.6063 ↑ 0.14	28.66 %	58.13 %	18.77 %	7.4 %
Nippon India Pharma Fund Growth	₹227.604 ↑ 0.44	28.66 %	59.68 %	19.56 %	7.83 %
Data as on 20 Oct 20

Disclaimer:
All efforts have been made to ensure the information provided here is accurate. However, no guarantees are made regarding correctness of data.

Shepard Technologies Pvt. Ltd : A -204, Technocity, Plot No X-4/1 & X-4/2, TTC, MIDC, Mahape, Navi Mumbai - 400710

AMFI Registration No. 112358 | CIN: U74999MH2016PTC282153

Mutual fund investments are subject to market risks. Please read the scheme information and other related documents carefully before investing. Past performance is not indicative of future returns. Please consider your specific investment requirements before choosing a fund, or designing a portfolio that suits your needs.

Shepard Technologies Pvt. Ltd. (with ARN code 112358) makes no warranties or representations, express or implied, on products offered through the platform. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or related services. Terms and conditions of the website are applicable.